TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8678327

Group type: EXPERIMENTAL
Intervention: Symptomatic diffuse atherosclerosis
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: History of multiple myocardial infarctions
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Reduced exercise performance
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Lower alcohol intake
Number of subjects: 4159
Study: 1814249

Group type: EXPERIMENTAL
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study: 6347741

Group type: EXPERIMENTAL
Intervention: Non-aggressive management (study group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surgical induction (control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study: 29175720

Group type: EXPERIMENTAL
Intervention: Olanzapine (n=131)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Risperidone (n=133)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 264
Study: 26450814

Group type: EXPERIMENTAL
Intervention: Dopamine depletion using an acute phenylalanine/tyrosine depletion drink
Number of subjects: 34

Group type: COMPARATOR
Intervention: Balanced amino acid drink (control condition)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dopamine depletion
Number of subjects: 34
Study: 24686513

Group type: EXPERIMENTAL
Intervention: Enhanced training model (N=31) with ongoing expert coaching, video review, and consultation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Three-day workshop model (N=25)
Number of subjects: 56
Study: 22047597

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 670-nm laser irradiation, 40 mW, 1.6 J, 2.04 J/cm(2), 51 mW/cm(2) per blister in the prodromal stage and 4.8 J in the crust and secondarily infected stages, plus 1.2 J at the C2-C3 vertebrae
Number of subjects: 232

Group type: COMPARATOR
Intervention: Conventional therapy including acyclovir cream or tablets
Number of subjects: 232
Study: 19444123

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study: 19441264

Group type: COMPARATOR
Intervention: Group A: Standard polymerization (Control) - Exposure for 20 seconds at 700 mW/cm2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B: Step polymerization - Exposure for 10 seconds at 100 mW/cm2 then 20 seconds at 700 mW/cm2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group C: Pulse polymerization - Exposure for 20 cycles, each cycle consists of 1 second at 700 mW/cm2 then 0.25 second at 0 mW/cm2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group D: Ramp polymerization - Exposure for 10 seconds with a slow rise of the intensity to reach 700 mW/cm2 then 20 seconds at 700 mW/cm2
Number of subjects: 120
Study: 15842517

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (120 mg three times daily)
Number of subjects: 0
Study: 15109758

Group type: EXPERIMENTAL
Intervention: Parkinson's patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 24
Study: 11742909

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 1,000 microg/d for 4 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Inhaled bronchodilator therapy (control group)
Number of subjects: 87
Study: 9031898

Group type: EXPERIMENTAL
Intervention: LAM (lansoprazole 30 mg once a day for 1 week, azithromycin 500 mg once a day for 3 days, metronidazole 250 mg twice a day for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: OCT (omeprazole, clarithromycin, tinidazole)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LAM
Number of subjects: 60
Study: 8339946

Group type: EXPERIMENTAL
Intervention: Orange dye laser (600 nm)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Blue‐green argon laser (488 and 514.5 nm)
Number of subjects: 14
Study: 3090600

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.9 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31226922

Group type: EXPERIMENTAL
Intervention: Dysphagia screen fail
Number of subjects: 11093

Group type: EXPERIMENTAL
Intervention: Dysphagia assessment fail
Number of subjects: 11093

Group type: EXPERIMENTAL
Intervention: Subsequent feeding restrictions after dysphagia screen or assessment fail
Number of subjects: 11093
Study: 27990746

Group type: EXPERIMENTAL
Intervention: Parent group intervention to manage restricted and repetitive behaviours (RRB) in young children with ASD.
Number of subjects: 14
Study: 27645372

Group type: EXPERIMENTAL
Intervention: Application of the 5‐CNL on all food products in three specific sections (breakfast cereals, sweet biscuits, appetizers)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Introduction of the 5‐CNL accompanied by consumer information on use and understanding of the label
Number of subjects: 901

Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 901
Study: 25479206

Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery (ESS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22442959

Group type: EXPERIMENTAL
Intervention: Cycloferon (500 mg)
Number of subjects: 35
Study: 20813705

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (CH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-continuous hemofiltration (NCH)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 19038698

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium bifidum and Lactobacillus plantarum 8PA3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy (abstinence plus vitamins)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium bifidum and Lactobacillus plantarum 8PA3) in subgroup of 26 subjects with mild alcoholic hepatitis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy (abstinence plus vitamins) in subgroup of 26 subjects with mild alcoholic hepatitis
Number of subjects: 66
Study: 16815777

Group type: EXPERIMENTAL
Intervention: Aqua exercise (walking, jogging, and jumping in water for 30 min each day for 3 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no aqua exercise)
Number of subjects: 10
Study: 12502973

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (ARS) with peak airway pressure of 40 cm H2O and PEEP of 15 cm H2O for 10 breaths, then reduced to 5 cm H2O.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) of 5 cm H2O without recruitment.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP) with no PEEP or recruitment maneuver.
Number of subjects: 24
Study: 10190532

Group type: EXPERIMENTAL
Intervention: Minimally invasive strategy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard percutaneous transluminal coronary angioplasty
Number of subjects: 23
Study: 7848119

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg every other day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Aspirin placebo (control group)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Beta-carotene placebo (control group)
Number of subjects: 22071
Study: 2335168

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 12
Study: 226735

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29543510

Group type: EXPERIMENTAL
Intervention: Open acromioplasty (OSG)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty (ASG)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Physical therapy group (PTG)
Number of subjects: 87
Study: 27093503

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Classic laryngoscope (CL)
Number of subjects: 34
Study: 24947443

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23176247

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids, γ‐linolenic acid, and antioxidants
Number of subjects: 272
Study: 20007824

Group type: EXPERIMENTAL
Intervention: Peripheral drusen associated with CFHY402H (CC versus TT genotypes)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with CFHY402H (CC versus TT genotypes)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with presence of 20 or more small, hard macular drusen
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with peripheral drusen
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: 20 or more small, hard macular drusen per eye
Number of subjects: 1107
Study: 18387797

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 100 microg twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 microg twice daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budesonide 200 mg/day (early treatment group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budesonide 800 mg/day (established symptoms)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 81
Study: 15761413

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus casei (n = 254)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Nonprobiotic yogurt (control group, n = 248)
Number of subjects: 541
Study: 12848110

Group type: EXPERIMENTAL
Intervention: NPF Psoriasis Score (NPF-PS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: PASI
Number of subjects: 33

Group type: COMPARATOR
Intervention: Physician's Global Assessment (PGA)
Number of subjects: 33
Study: 10327094

Group type: EXPERIMENTAL
Intervention: Supervised home-based programme (experimental group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Outpatient or day hospital therapy (control group)
Number of subjects: 100
Study: 7562021

Group type: EXPERIMENTAL
Intervention: alpha 2a-interferon (alpha 2a-INF) in combination with vinblastine
Number of subjects: 30

Group type: COMPARATOR
Intervention: radical nephrectomy and extended lymphadenectomy
Number of subjects: 30
Study: 2140375

Group type: EXPERIMENTAL
Intervention: Cholinergic REM sleep induction test in depressed patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cholinergic REM sleep induction test in eating disorder patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cholinergic REM sleep induction test in control subjects
Number of subjects: 50
Study: 7322956

Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 1 week
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 6 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 2, 4, and 6 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indapamide treatment
Number of subjects: 9
Study: 6428643

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral Pancreatic Function Test
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination of CT with either ultrasound or oral pancreatic function test
Number of subjects: 107
Study: 30741877

Group type: EXPERIMENTAL
Intervention: PJT-100
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PJT-80
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PJT-65
Number of subjects: 38

Group type: COMPARATOR
Intervention: CON
Number of subjects: 38
Study: 30536572

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring over 7 days
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Insulin pump use
Number of subjects: 233
Study: 29569718

Group type: EXPERIMENTAL
Intervention: HPV 16
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: HPV 35
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Single HPV 16
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Single HPV 35
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: HPV 31/33/35 group
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: HPV 18/45/51/52 group
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: HPV 39/56/58/59/66/68 group
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Multiple infections with HPV 16
Number of subjects: 820
Study: 25916689

Group type: EXPERIMENTAL
Intervention: Breast cancer survivors (BCS)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Body Stigma subscale of BI after Breast Cancer Questionnaire
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Vaginal dryness, body stigma, relationship satisfaction
Number of subjects: 127
Study: 24281411

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Self-help control group
Number of subjects: 141
Study: 22836303

Group type: EXPERIMENTAL
Intervention: PerMIT-guided management
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PerMIT S‐warfarin plasma concentration model
Number of subjects: 26
Study: 20434827

Group type: EXPERIMENTAL
Intervention: Mifepristone/misoprostol (MM) - 200 mg mifepristone orally followed by 400 microg misoprostol vaginally after 36-48 hours, with up to three additional doses of 400 microg misoprostol every 12 hours
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intra-amniotic injection of ethacridine lactate (EL) - 100 mg ethacridine lactate
Number of subjects: 210
Study: 18047001

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (MMC and placebo)
Number of subjects: 52
Study: 16566375

Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Non-smoking during pregnancy
Number of subjects: 147
Study: 11980761

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy
Number of subjects: 3611

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 3611
Study: 10550131

Group type: EXPERIMENTAL
Intervention: Group 1: Double the dose and intensity of cyclophosphamide (4 courses)
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Group 2: Same dose of cyclophosphamide as in Group 1 (2 courses, intensified)
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Group 3: Double the dose of cyclophosphamide (intensified and increased)
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Control Group (B-22 standard therapy)
Number of subjects: 2548
Study: 7541637

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 Mio KIU loading dose before sternotomy, followed by 0.5 Mio KIU/h infusion until end of surgery; 2 Mio KIU added to priming volume)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 2192440

Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ) 150 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Piperacillin (PIP) 200 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Piperacillin (PIP)
Number of subjects: 98
Study: 371036

Group type: EXPERIMENTAL
Intervention: guanabenz
Number of subjects: 18

Group type: COMPARATOR
Intervention: clonidine
Number of subjects: 18
Study: 31584453

Group type: EXPERIMENTAL
Intervention: Treadmill training with load (5% of body weight) on the nonparetic limb
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treadmill training without load
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 38
Study: 30350154

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) - 2×30 breaths, 40% maximal inspiratory pressure
Number of subjects: 8

Group type: COMPARATOR
Intervention: SHAM - 2×30 breaths, 15% maximal inspiratory pressure
Number of subjects: 8
Study: 28508398

Group type: EXPERIMENTAL
Intervention: PFME alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PFME + BF
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 25655792

Group type: EXPERIMENTAL
Intervention: 2-month supervised exercise programme including aerobic and strength exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care for cancer: optimized usual drug therapies and strengthening of self-care
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2-month supervised exercise programme
Number of subjects: 66
Study: 24736930

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard open discectomy
Number of subjects: 185
Study: 22856633

Group type: EXPERIMENTAL
Intervention: MP29-02 (intranasal formulation of azelastine hydrochloride and fluticasone propionate)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Azelastine (AZ)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 779
Study: 18854339

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (n=48)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 99
Study: 17515294

Group type: EXPERIMENTAL
Intervention: Devasid 250 mg/5 ml (test preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 375 mg/7.5 ml (reference preparation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Devasid (test preparation)
Number of subjects: 24
Study: 15354030

Group type: EXPERIMENTAL
Intervention: Resistance training (RST)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 10740332

Group type: EXPERIMENTAL
Intervention: 2 mg of 17beta‐oestradiol continuously combined with 1 mg of norethisterone acetate (E2+NETA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1.5 mg of piperazine oestrone sulphate plus 0.7 mg of norethisterone (highEP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.75 mg of piperazine oestrone sulphate plus 0.35 mg of norethisterone (lowEP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9361397

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vaginal ultrasound
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Endovaginal probe
Number of subjects: 66

Group type: COMPARATOR
Intervention: Transabdominal sonography
Number of subjects: 66
Study: 8476831

Group type: EXPERIMENTAL
Intervention: Prophylactic progestogen in addition to conventional therapy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 257
Study: 3084316

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) with chlorpromazine (CPZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium with chlorpromazine (CPZ)
Number of subjects: 30
Study: 29122372

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - single-dose cohort
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - multiple-dose cohort
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - combined cohorts
Number of subjects: 76
Study: 28460717

Group type: EXPERIMENTAL
Intervention: Handheld, pocket‐sized ultrasound for diagnosing distal radius fractures
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Handheld, pocket‐sized ultrasound for assessing reduction adequacy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interrater reliability between musculoskeletal radiologist and hand surgeon
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intrarater reliability
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (standard radiographic and ultrasonographic examination)
Number of subjects: 23
Study: 25393566

Group type: EXPERIMENTAL
Intervention: Prone position (n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Supine position (n=26)
Number of subjects: 52
Study: 23429918

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg three times daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21789702

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Droperidol (1.25 mg)
Number of subjects: 361
Study: 18443390

Group type: EXPERIMENTAL
Intervention: Parent-only cognitive behavioral therapy (CBT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Parent-child cognitive behavioral therapy (CBT)
Number of subjects: 56
Study: 17156624

Group type: EXPERIMENTAL
Intervention: T3 sympathectomy (Group B, n = 131)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: T3-4 sympathectomy (Group C, n = 60)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Combined group (Group B + C)
Number of subjects: 398

Group type: COMPARATOR
Intervention: T2-4 sympathectomy (Group A, n = 207)
Number of subjects: 398